Elia Seguí: Can some early HER2+ BC be treated without chemotherapy
Elia Seguí, Predoctoral Researcher at Translational Genomics and Targeted therapies in Solid Tumors at August Pi i Sunyer Biomedical Research Institute, shared a post on X:
”Just out in The Lancet Oncology. Can some early HER2+ BC be treated without chemotherapy?
WSG-KEYRICHED-1 tested trastuzumab+ pertuzumab+pembro in PAM50 HER2-E tumors
pCR: 47% (below threshold but promising)
0% pCR if ctDNA+ at BL & not cleared by week 3.”
Title: Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
Journal: The Lancet Oncology
Authors: Sherko Kuemmel, Monika Graeser, Peter Schmid, Mattea Reinisch, Friedrich Feuerhake, Valery Volk, Sorin Armeanu-Ebinger, Leon Schütz, Olga Kelemen, Christopher Schroeder, Stephan Ossowski, Katarzyna Jóźwiak, Athina Kostara, Iris Scheffen, Kerstin Lüdtke-Heckenkamp, Felix Hilpert, Angela Kentsch, Carsten Ziske, Reinhard Depenbusch, Michael Braun, Jens Uwe Blohmer, Christine zu Eulenburg, Matthias Christgen, Stephan Bartels, Hans Heinrich Kreipe, Rachel Wuerstlein, Claudia Biehl, Enrico Pelz, Andreas Hartkopf, Nadia Harbeck, Oleg Gluz
Read the Full Article.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023